WASHINGTON - Government health advisers will meet later this month to review a highly anticipated artery-opening device from Abbott Laboratories. The Food and Drug Administration’s panel of heart experts will consider the safety and effectiveness of Abbott’s Xience drug-coated stent on Nov. 29. The agency is not required to follow the recommendations of its panels, though it usually does.
